BSP:VRTX34 (USA)  
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

R$ 392.34 (+2.86%) Oct 5
P/E:
22.77
P/B:
6.04
Market Cap:
R$ 391.28B ($ 75.56B)
Enterprise V:
R$ 354.92B ($ 68.54B)
Volume:
2.00
Avg Vol (2M):
1.04K
Also Trade In:
Volume:
2.00
Market Cap R$:
391.28B
Market Cap $:
75.56B
PE Ratio:
22.77
Avg Vol (2-Month):
1.04K
Enterprise Value R$:
354.92B
Enterprise Value $:
68.54B
PB Ratio:
6.04
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Financials (Next Earnings Date:2022-11-02 Est.)

BSP:VRTX34's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil R$) 43,718.285
EPS (TTM) (R$) 16.203
Beta -0.1
Volatility % 25.42
14-Day RSI 53.96
14-Day ATR (R$) 6.397897
20-Day SMA (R$) 375.573
12-1 Month Momentum % 47.62
52-Week Range (R$) 247.08 - 400
Shares Outstanding (Mil) 1,025.84

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 8
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Vertex Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Vertex Pharmaceuticals Inc Analysis

Share your research